<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Avacta Group Plc — News on 6ix</title>
<link>https://6ix.com/company/avacta-group-plc</link>
<description>Latest news and press releases for Avacta Group Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/avacta-group-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835e09578dffbe2df126109.webp</url>
<title>Avacta Group Plc</title>
<link>https://6ix.com/company/avacta-group-plc</link>
</image>
<item>
<title>Avacta data AACR underline AVA6103 profile</title>
<link>https://6ix.com/company/avacta-group-plc/news/avacta-data-aacr-underline-ava6103-profile</link>
<guid isPermaLink="true">https://6ix.com/company/avacta-group-plc/news/avacta-data-aacr-underline-ava6103-profile</guid>
<pubDate>Tue, 21 Apr 2026 06:00:00 GMT</pubDate>
<description>Avacta Group PLC presented preclinical and early clinical data at AACR 2026 highlighting the favorable profile of AVA6103 and the advantages of its pre|CISION® delivery platform. Data showed AVA6103 exhibits robust activity in PDX models with low FAP expression and a more favorable kinetic profile compared to Enhertu®, with a tumor Cmax over one log higher and a Tumor Selectivity Index three times greater. The company also showcased the dual payload capability of its pre|CISION® platform with in</description>
</item>
<item>
<title>Christina Coughlin - In Vivo 2026 Rising Leader</title>
<link>https://6ix.com/company/avacta-group-plc/news/christina-coughlin-in-vivo-2026-rising-leader</link>
<guid isPermaLink="true">https://6ix.com/company/avacta-group-plc/news/christina-coughlin-in-vivo-2026-rising-leader</guid>
<pubDate>Tue, 14 Apr 2026 10:37:00 GMT</pubDate>
<description>Avacta Therapeutics announced that its CEO, Christina Coughlin, has been recognized as one of In Vivo's 2026 Rising Leaders, highlighting her innovative contributions to oncology drug development. The company also noted the rapid progress of its drug candidate AVA6103, which moved from discovery to patient treatment in a Phase 1a trial within 24 months, demonstrating the effectiveness of its pre|CISION® platform in delivering potent therapies directly to tumors while minimizing systemic exposure</description>
</item>
<item>
<title>Q1 2026 Business Update</title>
<link>https://6ix.com/company/avacta-group-plc/news/q1-2026-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/avacta-group-plc/news/q1-2026-business-update</guid>
<pubDate>Thu, 09 Apr 2026 06:00:00 GMT</pubDate>
<description>Avacta Group PLC reported significant progress in Q1 2026, with its first Gen Two program, AVA6103, initiating its Phase 1 clinical trial and treating its first patient, following IND clearance and promising preclinical data showing superior tumor penetration and selectivity compared to Enhertu. The Gen One program, AVA6000, saw positive health authority interactions leading to the removal of the lifetime maximum dose due to favorable cardiac safety, and dose selection for future trials was agre</description>
</item>
<item>
<title>Avacta Announces Science Day 2026</title>
<link>https://6ix.com/company/avacta-group-plc/news/avacta-announces-science-day-2026</link>
<guid isPermaLink="true">https://6ix.com/company/avacta-group-plc/news/avacta-announces-science-day-2026</guid>
<pubDate>Wed, 08 Apr 2026 06:00:00 GMT</pubDate>
<description>Avacta Group PLC has announced its 2026 Science Day event, titled "The Next Chapter of pre|CISION," scheduled for May 6, 2026, in Central London. The event will feature presentations from Avacta team members on the company's scientific progress and future aspirations, followed by a reception. Attendance is limited and will be allocated on a first-come, first-served basis, with a professionally recorded video of the event to be made available online for those unable to attend in person.
</description>
</item>
<item>
<title>First patient treated in Phase 1 trial of AVA6103</title>
<link>https://6ix.com/company/avacta-group-plc/news/first-patient-treated-in-phase-1-trial-of-ava6103</link>
<guid isPermaLink="true">https://6ix.com/company/avacta-group-plc/news/first-patient-treated-in-phase-1-trial-of-ava6103</guid>
<pubDate>Tue, 31 Mar 2026 06:00:00 GMT</pubDate>
<description>Avacta Group PLC announced that the first patient has been treated in its Phase 1 FOCUS-01 trial for FAP-Exd (AVA6103), a sustained-release peptide drug conjugate designed to selectively deliver payloads to tumors. This marks a significant milestone for their oncology pipeline, with initial data expected later this year. The company also recently completed a £10 million fundraise, extending its cash runway into early Q1 2027, which is anticipated to provide sufficient funding beyond the initial </description>
</item>
<item>
<title>Result of Oversubscribed Fundraise</title>
<link>https://6ix.com/company/avacta-group-plc/news/result-of-oversubscribed-fundraise-2</link>
<guid isPermaLink="true">https://6ix.com/company/avacta-group-plc/news/result-of-oversubscribed-fundraise-2</guid>
<pubDate>Fri, 27 Mar 2026 07:00:00 GMT</pubDate>
<description>Avacta Group plc has successfully raised £10 million through an oversubscribed placing and subscription of new ordinary shares at 63 pence per share. This includes a £550,000 subscription by directors Richard Hughes and David Bryant. The company also agreed to issue warrants to Zeus Capital for 4,364,457 ordinary shares, representing 0.96% of the enlarged share capital, exercisable at 63 pence per share for five years. These transactions, including Zeus Capital's participation in the placing, ar</description>
</item>
<item>
<title>Proposed Fundraise to raise approximately £10m</title>
<link>https://6ix.com/company/avacta-group-plc/news/proposed-fundraise-to-raise-approximately-pound10m</link>
<guid isPermaLink="true">https://6ix.com/company/avacta-group-plc/news/proposed-fundraise-to-raise-approximately-pound10m</guid>
<pubDate>Thu, 26 Mar 2026 17:16:00 GMT</pubDate>
<description>Avacta Group plc is proposing a fundraising to raise approximately £10 million through a placing and subscription at an issue price of 63 pence per new ordinary share. This equity raise is intended to provide further working capital for the company's research and development programs, extending its cash runway into early Q1 2027 and beyond the expected initial data readout of the AVA6103 (FAP-Exd) Phase 1a trial in late 2026. The fundraising is also supported by intended subscriptions from two N</description>
</item>
<item>
<title>Issue of Equity</title>
<link>https://6ix.com/company/avacta-group-plc/news/issue-of-equity-227</link>
<guid isPermaLink="true">https://6ix.com/company/avacta-group-plc/news/issue-of-equity-227</guid>
<pubDate>Thu, 26 Mar 2026 16:44:00 GMT</pubDate>
<description>Avacta Group plc is proposing a placing and subscription to raise approximately £10 million at an issue price of 63 pence per new ordinary share. This fundraising is intended to provide working capital for research and development programs through early Q1 2027 and extend the cash runway beyond the initial data readout of the AVA6103 (FAP-Exd) Phase 1a trial, expected in late 2026. The company is also progressing with Phase 1b expansion cohorts of faridoxorubicin (AVA6000) and expects to release</description>
</item>
<item>
<title>Presentations of pre|CISION® Platform Candidates</title>
<link>https://6ix.com/company/avacta-group-plc/news/presentations-of-preorcisionr-platform-candidates</link>
<guid isPermaLink="true">https://6ix.com/company/avacta-group-plc/news/presentations-of-preorcisionr-platform-candidates</guid>
<pubDate>Tue, 17 Mar 2026 07:00:00 GMT</pubDate>
<description>Avacta Group PLC announced that it will present preclinical and translational data for its pre|CISION® platform candidates at the 2026 AACR Annual Meeting from April 17-22, 2026. Two presentations will detail AVA6103, a FAP-enabled peptide-drug conjugate delivering exatecan with sustained release and potent antitumor activity, and novel pre|CISION® compounds designed to deliver complementary dual payloads to the tumor microenvironment following FAP cleavage. These presentations highlight the com</description>
</item>
<item>
<title>Phase 1 study opening for AVA6103</title>
<link>https://6ix.com/company/avacta-group-plc/news/phase-1-study-opening-for-ava6103</link>
<guid isPermaLink="true">https://6ix.com/company/avacta-group-plc/news/phase-1-study-opening-for-ava6103</guid>
<pubDate>Mon, 16 Mar 2026 07:00:00 GMT</pubDate>
<description>Avacta Group PLC has announced the opening of its Phase 1 trial for FAP-Exd (AVA6103), a sustained-release peptide-drug conjugate utilizing the pre|CISION® platform, with the first patient expected to enroll before the end of March. This trial will evaluate the safety, pharmacokinetics, and preliminary efficacy of AVA6103 in patients with advanced pancreatic, cervical, vulvar, gastric, gastroesophageal junction, or small cell lung cancers, with parallel arms investigating two administration sche</description>
</item>
<item>
<title>Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis</title>
<link>https://6ix.com/company/avacta-group-plc/news/avactas-preorcision-mechanism-for-payload-delivery-shows-key-advantages-compared-to-an-antibody-drug-conjugate-in-innovative-ai-driven-analysis</link>
<guid isPermaLink="true">https://6ix.com/company/avacta-group-plc/news/avactas-preorcision-mechanism-for-payload-delivery-shows-key-advantages-compared-to-an-antibody-drug-conjugate-in-innovative-ai-driven-analysis</guid>
<pubDate>Tue, 24 Feb 2026 07:00:00 GMT</pubDate>
<description>Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu® Clinical trial with AVA6103 is expected to be initiated in Q1 2026 LONDON and PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today published new data which demonstrates the favorable de</description>
</item>
<item>
<title>PreCISION payload delivery advantage over ADC</title>
<link>https://6ix.com/company/avacta-group-plc/news/precision-payload-delivery-advantage-over-adc</link>
<guid isPermaLink="true">https://6ix.com/company/avacta-group-plc/news/precision-payload-delivery-advantage-over-adc</guid>
<pubDate>Tue, 24 Feb 2026 07:00:00 GMT</pubDate>
<description>Avacta Group PLC announced that experimental data for its pre|CISION mechanism, specifically FAP-Exd (AVA6103), demonstrates significant advantages over the marketed antibody drug conjugate Enhertu®, including more rapid tumor penetration, a one log higher absolute maximum drug concentration in the tumor, and a nearly three-fold higher Tumor Selectivity Index. The company expects to initiate a Phase 1 clinical trial for AVA6103 in Q1 2026, with the AI-driven analysis supporting increased confide</description>
</item>
<item>
<title>Avacta to Participate in Conference March 2026</title>
<link>https://6ix.com/company/avacta-group-plc/news/avacta-to-participate-in-conference-march-2026</link>
<guid isPermaLink="true">https://6ix.com/company/avacta-group-plc/news/avacta-to-participate-in-conference-march-2026</guid>
<pubDate>Wed, 18 Feb 2026 07:00:00 GMT</pubDate>
<description>Avacta Group PLC announced that its executive management team will participate in the TD Cowen Health Care Conference in Boston on March 3, 2026. The CEO and CFO will host investor meetings and deliver a live company presentation at 9:10 AM ET, with a replay to be available on the company's investor resources website.
Disclaimer*</description>
</item>
<item>
<title>Appointment of CSO</title>
<link>https://6ix.com/company/avacta-group-plc/news/appointment-of-cso</link>
<guid isPermaLink="true">https://6ix.com/company/avacta-group-plc/news/appointment-of-cso</guid>
<pubDate>Mon, 09 Feb 2026 12:00:00 GMT</pubDate>
<description>Avacta Therapeutics has appointed Francis Wilson as Chief Scientific Officer, succeeding Michelle Morrow. Wilson, who joined Avacta in September 2022 as Vice President of Chemistry, has been instrumental in developing the company's pre|CISION® platform and novel intellectual property, particularly the sustained release mechanism for the FAP-Exd (AVA6103) program, which is nearing clinical testing. His extensive experience in medicinal chemistry, including previous roles at Roche, Xenova, Cellzom</description>
</item>
<item>
<title>Avacta appoints Francis Wilson as Chief Scientific Officer</title>
<link>https://6ix.com/company/avacta-group-plc/news/avacta-appoints-francis-wilson-as-chief-scientific-officer</link>
<guid isPermaLink="true">https://6ix.com/company/avacta-group-plc/news/avacta-appoints-francis-wilson-as-chief-scientific-officer</guid>
<pubDate>Mon, 09 Feb 2026 07:00:00 GMT</pubDate>
<description>LONDON and PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, has appointed Francis Wilson as its Chief Scientific Officer. Since joining Avacta in September 2022 as Vice President of Chemistry, Francis has demonstrated his extensive expertise and experience in the chemistry field, particularly in the development of the Company's</description>
</item>
<item>
<title>Faridoxorubicin Program Clinical Updates</title>
<link>https://6ix.com/company/avacta-group-plc/news/faridoxorubicin-program-clinical-updates</link>
<guid isPermaLink="true">https://6ix.com/company/avacta-group-plc/news/faridoxorubicin-program-clinical-updates</guid>
<pubDate>Tue, 03 Feb 2026 12:00:00 GMT</pubDate>
<description>Avacta Group PLC has announced significant clinical updates for its faridoxorubicin program, removing the cardiac dosing limit and identifying a path for dose selection in future efficacy studies. This decision stems from highly favorable safety data, allowing patients to receive nearly four times the conventional doxorubicin dose and a maximum cumulative exposure of 550 mg/m² without severe cardiac toxicity. The company will now enroll final Phase 1b cohorts to compare two dose levels, aiming t</description>
</item>
<item>
<title>Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Program</title>
<link>https://6ix.com/company/avacta-group-plc/news/avacta-announces-two-key-clinical-updates-to-its-faridoxorubicin-program</link>
<guid isPermaLink="true">https://6ix.com/company/avacta-group-plc/news/avacta-announces-two-key-clinical-updates-to-its-faridoxorubicin-program</guid>
<pubDate>Tue, 03 Feb 2026 12:00:00 GMT</pubDate>
<description>Cardiac dosing limit removed and path forward to dose selection identifiedLONDON and PHILADELPHIA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, has published two key clinical updates to its faridoxorubicin (AVA6000) clinical program. Agreed updates to the trial protocol include the removal of the maximum dosing limit and to allow flexibil</description>
</item>
<item>
<title>Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)</title>
<link>https://6ix.com/company/avacta-group-plc/news/avacta-announces-u-food-drug-130300170</link>
<guid isPermaLink="true">https://6ix.com/company/avacta-group-plc/news/avacta-announces-u-food-drug-130300170</guid>
<pubDate>Wed, 21 Jan 2026 13:03:00 GMT</pubDate>
<description>The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026 LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company’s second program FAP-Exd (AVA6103), the fi</description>
</item>
<item>
<title>FDA Clearance of IND Application for AVA6103</title>
<link>https://6ix.com/company/avacta-group-plc/news/fda-clearance-of-ind-application-for-ava6103</link>
<guid isPermaLink="true">https://6ix.com/company/avacta-group-plc/news/fda-clearance-of-ind-application-for-ava6103</guid>
<pubDate>Wed, 21 Jan 2026 12:00:00 GMT</pubDate>
<description>Avacta Group PLC announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for FAP-Exatecan (AVA6103), its second pre|CISION® medicine, a peptide drug conjugate utilizing the potent topoisomerase I inhibitor exatecan. The Phase 1 clinical study, which will assess safety and identify optimal dosing for pancreatic, cervical, gastric, and small cell lung cancers, is expected to commence in Q1 2026, with preliminary data anticipated in the second</description>
</item>
<item>
<title>Year-end trading update</title>
<link>https://6ix.com/company/avacta-group-plc/news/year-end-trading-update-2</link>
<guid isPermaLink="true">https://6ix.com/company/avacta-group-plc/news/year-end-trading-update-2</guid>
<pubDate>Tue, 20 Jan 2026 12:01:00 GMT</pubDate>
<description>Avacta Group plc reported significant progress in 2025, raising £22.5 million in equity to fund its research and development programs, with unaudited cash reserves of £16.9 million as of December 31, 2025, providing a runway into Q3 2026. The company achieved encouraging efficacy and safety data for its faridoxorubicin (AVA6000) program, with a 90% disease control rate in salivary gland cancer patients, and anticipates clinical testing for its FAP-Exd (AVA6103) program to commence in Q1 2026, wi</description>
</item>
</channel>
</rss>